02.07.13
Argenta, a Galapagos NV company, has signed a collaboration agreement with ANTABIO to provide medicinal chemistry, computer-aided drug design and ADME/PK services to assist ANTABIO in the identification and development of novel anti-bacterial agents.
ANTABIO is developing new drugs to work with existing antibiotics to enable them to regain activity against multi- or pan-drug resistant Gram-negative pathogens such as NDM-1 bacteria. ANTABIO’s compounds will also prevent infections caused by virulent and multi-drug resistant bacteria such as E.coli.
Dr. John Montana, managing director of Argenta, said, “Argenta is proud to announce this agreement with ANTABIO, which is the second SDDI-funded collaboration to be disclosed by Argenta in recent months. There is an urgent need for new anti-bacterial drugs and we look forward to working with ANTABIO to progress their compounds rapidly towards preclinical candidate nomination.”
“We are very excited to collaborate with Argenta on this SDDI-funded program” said Dr. Marc Lemonnier, chief executive officer of ANTABIO. “Assembling an expert and complementary drug discovery team is critical when it comes to advancing novel drugs that are so badly needed by patients suffering from life-threatening infections. This joint effort nicely exemplifies our vision of high-value partnering as a key element to deliver tomorrow’s antibacterial agents.”
ANTABIO is developing new drugs to work with existing antibiotics to enable them to regain activity against multi- or pan-drug resistant Gram-negative pathogens such as NDM-1 bacteria. ANTABIO’s compounds will also prevent infections caused by virulent and multi-drug resistant bacteria such as E.coli.
Dr. John Montana, managing director of Argenta, said, “Argenta is proud to announce this agreement with ANTABIO, which is the second SDDI-funded collaboration to be disclosed by Argenta in recent months. There is an urgent need for new anti-bacterial drugs and we look forward to working with ANTABIO to progress their compounds rapidly towards preclinical candidate nomination.”
“We are very excited to collaborate with Argenta on this SDDI-funded program” said Dr. Marc Lemonnier, chief executive officer of ANTABIO. “Assembling an expert and complementary drug discovery team is critical when it comes to advancing novel drugs that are so badly needed by patients suffering from life-threatening infections. This joint effort nicely exemplifies our vision of high-value partnering as a key element to deliver tomorrow’s antibacterial agents.”